Stuart Hogarth

Publications (11) View all

• Article: Biomarker patents for diagnostics: problem or solution?

  Michael M Hopkins, Stuart Hogarth
  Nature Biotechnology 01/2012; 30(6):498-500. · 29.50 Impact Factor
• Article: A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA.

  Stuart Hogarth, Michael M Hopkins, Victor Rodriguez
  [show abstract] [hide abstract]
  ABSTRACT: DNA-based molecular testing for human papillomavirus has emerged as a novel approach to cervical cancer screening in the context of well-entrenched existing technology, the Pap smear. This article seeks to elucidate the process of molecularisation in the context of screening programmes. We illustrate how, although Pap has long been problematised and could be seen as a competing technological option, the existing networks and regime for Pap were important in supporting the entrenchment process for the artefacts, techniques and new diagnostics industry entrant, Digene, associated with the new test. The article provides insights into how the molecularisation of screening unfolds in a mainstream market. We reveal an incremental and accretive, rather than revolutionary, process led by new commercial interests in an era when diagnostic innovation is increasingly privatised. We show Digene's reliance on patents, an international scientific network and their position as an obligatory point of passage in the clinical research field with regard to the new technology's role, as well as on controversial new marketing practices. The article is based on a mixed method approach, drawing on a wide range of contemporary sources (including patents, statutory filings by companies, scientific literature and news sources) as well as interviews.
  Sociology of Health & Illness 11/2011; 34(2):234-50. · 1.88 Impact Factor
• Source

  Available from: Martina C Cornel

  Article: Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders.

  Frauke Becker, Carla G van El, Dolores Ibarreta, Eleni Zika, Stuart Hogarth, Pascal Borry, Anne Cambon-Thomsen, Jean Jacques Cassiman, Gerry Evers-Kiebooms, Shirley Hodgson, [......], Victor B Penchaszadeh, Andrew Read, Wolf Rogowski, Jorge Sequeiros, Lisbeth Tranebjaerg, Irene M van Langen, Helen Wallace, Ron Zimmern, Jörg Schmidtke, Martina C Cornel
  European journal of human genetics: EJHG 04/2011; 19 Suppl 1:S6-44. · 3.56 Impact Factor
• Source

  Available from: Martina C Cornel

  Article: Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities

  Frauke Becker, Carla G van El, Dolores Ibarreta, Eleni Zika, Stuart Hogarth, Pascal Borry, Anne Cambon-Thomsen, Jean Jacques Cassiman, Gerry Evers-Kiebooms, Shirley Hodgson, [......], Victor B Penchaszadeh, Andrew Read, Wolf Rogowski, Jorge Sequeiros, Lisbeth Tranebjaerg, Irene M van Langen, Helen Wallace, Ron Zimmern, J|[ouml]|rg Schmidtke, Martina C Cornel
  European Journal of HumanGenetics 03/2011; · 4.40 Impact Factor
• Source

  Available from: univr.it

  Article: The future of direct-to-consumer clinical genetic tests.

  Felix W Frueh, Henry T Greely, Robert C Green, Stuart Hogarth, Sue Siegel
  [show abstract] [hide abstract]
  ABSTRACT: In light of the meeting of the US Food and Drug Administration (FDA) in March 2011 to discuss the regulation of clinical direct-to-consumer (DTC) genetic tests, we have invited five experts to consider the best means of overseeing the ordering and interpretation of these tests. Should these tests be regulated? If so, who, if anyone, should communicate results to consumers?
  Nature Reviews Genetics 01/2011; 12(7):511-5. · 38.08 Impact Factor